Thursday 16 October, 2025
Objective: The objective of the work presented here is to optimize the design and analysis of a Phase II proof-of-concept…
Read moreoral presentation
Population pharmacokinetics/-dynamics of dabigatran, the active form of the new oral direct thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing hip replacement
Thursday 16 October, 2025
Introduction: The oral direct thrombin inhibitor prodrug dabigatran etexilate is under development for the prevention of thrombosis in patients at…
Read morePatient adherence and the evolution of resistance to anti-viral agents
Thursday 16 October, 2025
The paper will discuss recent work on the interplay between patient adherence and the evolution of drug resistance in HIV-1…
Read moreEvaluation of a Random Sparse Sampling Design: An Assessment of Power and Bias Using Simulation
Thursday 16 October, 2025
Objectives: Assess power and sample size requirements for a population pharmacokinetic (PK) substudy of a phase III clinical trial using…
Read moreDesign and power PK/PD experiments using very sparse data
Thursday 16 October, 2025
Objectives: The design of PK/PD experiments is a critical issue for improving the efficiency of pharmacology trials. An optimal design…
Read moreUsing SAS for non-linear mixed modelling – An overview
Thursday 16 October, 2025
PDF of presentation The NLMIXED procedure in SAS fits nonlinear mixed models, that is, models in which both fixed and…
Read moreAn Application of Modelling and Simulation to Type 2 Diabetes: Development of a general drug-disease model based on a meta analysis of over 40 studies investigating 5 PPAR drugs
Thursday 16 October, 2025
PDF of presentation The PPARγ / PPARαγ class of drugs represent an excellent addition to the pharmacotherapeutic choices for the…
Read moreDisease progression modelling; application of population analysis to distinguish between symptomatic and protective treatment effects.
Thursday 16 October, 2025
Background: For certain diseases, drug treatment effects can only be evaluated relative to the disease progression over time. Model analysis…
Read moreComparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients
Thursday 16 October, 2025
Objective: S-1 is an oral anticancer agent combining tegafur (FT), a prodrug of 5-fluorouracil (5-FU), with potassium oxonate (oteracil) and…
Read morePopulation Pharmacokinetic Modelling of a Subcutaneous Depot for GnRH Antagonist Degarelix
Thursday 16 October, 2025
Objectives: The objective of the present analysis is to develop a population pharmacokinetic model that describes the spontaneous subcutaneous (SC)…
Read more